You are here

Press Release Archive

- Pfizer Reaffirms Leadership in International Corporate Volunteerism by Deploying the Largest Round of Global Health Fellows

(BUSINESS WIRE)-- Pfizer Inc today announced the eighth class of Global Health Fellows, a group of 28 Pfizer colleagues from North America, Europe and Asia, who will partner with non-governmental organizations (NGOs) and multilateral organizations (MLOs) in developing countries to help build health care infrastructure while on dedicated 4-6 month assignments. The Pfizer Global Health Fellows program is one of the first public-

- Adding Lipitor Early to Effective Blood Pressure Treatment Provided a Significant Reduction in Heart Attacks or Deaths from Heart Attacks over Five Years

(BUSINESS WIRE)--The early addition of Lipitor® (atorvastatin calcium) Tablets to effective blood pressure lowering treatment maintained a significant 36 percent reduction in the relative risk of fatal or non-fatal heart attacks over five years, according to a new analysis. This was a post-hoc analysis (designed and completed following the closure of the trial) of the lipid-lowering arm of the Anglo-Scandinavian Cardiac

- Pfizer and Scil Finalize Agreement for Novel Cartilage Growth Factor

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) and Scil Technology GmbH (Scil) have signed a licensing agreement for worldwide collaboration on Scil’s cartilage specific growth factor CD-RAP. Under this agreement, Pfizer will obtain a worldwide exclusive license to develop and commercialize CD-RAP. In addition to receiving royalties on the sale of any products that may be commercialised under this agreement, Scil is eligible for

- News & Media Press Releases Press Release Archive Press Statements Archive Featured Stories Video Gallery Frequently Requested Info Press Kits Download Multimedia Social Media Contact Pfizer Media Rela

(BUSINESS WIRE)--European vets are about to be given the same powerful medical tool which has helped U.S. vets manage obese dogs who don’t respond to exercise and diet. Since Pfizer Animal Health’s SLENTROLTM was introduced eight months ago in the U.S., thousands of obese dogs have benefited from healthier weights and more active lives. Now, European vets will be able to talk to dog owners about Slentrol as

- Patients Treated with Lipitor Were Significantly Less Likely to Have a Cardiovascular Event Than Those Treated with Simvastatin, New Observational Study Shows

(BUSINESS WIRE)-- Results of an observational study of a large U.S. managed care claims database showed that new statin users without cardiovascular disease who took Lipitor® (atorvastatin calcium) Tablets had a significantly lower relative risk of experiencing any cardiovascular event, a heart attack, or revascularization (a type of heart surgery) compared to patients who took simvastatin. Patients taking Lipitor had a

- Pfizer Receives Initial Communication from U.S. Patent and Trademark Office Regarding Lipitor Basic Patent

(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued its first communication in the reexamination of the ‘893 basic patent for Lipitor, initially rejecting the patent’s claims. This initial action, which is how the Office raises its issues with the patentee, will now be followed by the company’s response, in which Pfizer will address those issues raised by the examiner. As the

- Pfizer Wins Key New York State Court Ruling on Celebrex

(BUSINESS WIRE)--Pfizer Inc announced today that a New York state court ruled in favor of the company on an important motion relating to litigation over Pfizer’s Celebrex medication. New York Supreme Court Justice Shirley W. Kornreich ruled that the plaintiffs suing Pfizer in New York failed to present reliable scientific evidence necessary to prove that Celebrex can cause heart attacks and strokes at 200 mg daily – the most

- Pfizer Invites Public to View and Listen to Webcast of January 23 Conference Call with Analysts

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 12 Noon EST on Wednesday, January 23. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2007 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report,

- ADDING MULTIMEDIA Pfizer Names Sally Susman Senior Vice President of Worldwide Communications and Chief Communications Officer

(BUSINESS WIRE)--Pfizer Inc today named Sally Susman Senior Vice President of Worldwide Communications and Chief Communications Officer with overall responsibility for Pfizer’s global communications, reporting to Chairman and Chief Executive Officer Jeff Kindler. She will join Pfizer’s Executive Leadership Team. Ms. Susman is a communications executive with wide experience in corporate communications, media

- DoveBid(R) to Conduct Online Auction for Pfizer Japan

(BUSINESS WIRE)--DoveBid, Inc., the leading global provider of capital asset auction and valuation services, announced today that it will conduct a series of biotech and pharmaceutical lab equipment sales via a featured online auction (FOA) for Pfizer Japan, Inc.’s laboratory located in Nagoya, Japan. Pfizer is a global leader in the development, production, marketing and sales of innovative healthcare products. The

- Pfizer to Appeal Canadian Federal Court Ruling on Lipitor Patent; Court's Decision Will Have No Immediate Commercial Impact

(BUSINESS WIRE)--Pfizer Inc said today it will appeal a Canadian Federal Court decision in favor of generic manufacturer Apotex in its challenge to a Pfizer patent covering Lipitor. The court denied Pfizer’s request to prevent Apotex from launching a generic version of Lipitor prior to the expiration of Pfizer’s enantiomer (calcium salt) patent in July 2010. The court’s decision has no immediate commercial

- Talking to a Doctor about Smoking Makes Quitting Easier - New Survey Reveals

(BUSINESS WIRE)--84 percent of ex-smokers who consulted with their doctor or another healthcare professional during their final successful quit attempt believe that giving up would have been more difficult if they had tried to quit alone – according to the results of a new European survey announced today.(1) The survey, which investigated the attitudes of nearly 1,000 ex-smokers on smoking and smoking cessation, revealed that 74 percent

- Pfizer Inc Announces Completion of the Tender Offer Relating to Outstanding Shares of Coley Pharmaceutical Group, Inc.

(BUSINESS WIRE)--Pfizer (NYSE:PFE) announced today that it has completed the cash tender offer to purchase all of the outstanding shares of common stock of Coley Pharmaceutical Group, Inc. (Nasdaq:COLY). The tender offer expired, as scheduled, at midnight, Eastern time, on Friday, December 28, 2007. The offer was not extended. A total of 24,050,054 shares of Coley common stock were validly tendered and not withdrawn prior to the

- Pfizer Receives Approvable Letter from FDA for Dalbavancin

(BUSINESS WIRE)--Pfizer Inc today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) issued for dalbavancin HCl, Pfizer’s once-weekly two-dose antibiotic under FDA review for the treatment of adult patients with complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The FDA recently published a draft guidance

- Pfizer Statement on Results of Comparative Analysis of Tropism Assays

(BUSINESS WIRE)--Pfizer Inc recently conducted a comparative analysis of the tropism assays TrofileTM, provided by Monogram Biosciences, and SensiTropTM, provided by Pathway Diagnostics. This analysis of 100 treatment experienced patient samples showed that the SensiTrop results were discordant with the results obtained using Trofile, which was used and clinically validated in the SelzentryTM (maraviroc) clinical trials

- Pfizer to Acquire CovX to Extend Biotherapeutics Investment

(BUSINESS WIRE)--Pfizer Inc announced today it has entered into an agreement to acquire CovX, a privately-held biotherapeutics company specializing in preclinical oncology and metabolic research and a developer of a biotherapeutics technology platform that will enhance Pfizer’s biologic portfolio. “The acquisition of CovX is a further step in Pfizer’s strategy to acquire and identify new product candidates

- Pfizer Inc Clears Antitrust Review for Acquisition of All Outstanding Shares of Coley Pharmaceutical Group, Inc.

(BUSINESS WIRE)--Pfizer (NYSE:PFE) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired, and that it has received clearance from the Federal Cartel Office of Germany (FCO), in each case in connection with its offer to purchase all of the outstanding shares of common stock of Coley Pharmaceutical Group, Inc. (Nasdaq:COLY). Expiration of the waiting period under

- Pfizer Declares a 32-Cent First Quarter, 2008, Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 32-cent first–quarter, 2008, dividend on the company’s common stock, payable March 4, 2008, to shareholders of record at the close of business on February 8, 2008. Pfizer increased the dividend by approximately 10 percent from 29 cents to 32 cents per share as part of the Company’s continued commitment to enhancing shareholder return


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.